Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) is expected to release its results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($13.30) per share and revenue of $2.80 million for the quarter.
Catheter Precision Stock Performance
Shares of NYSEAMERICAN:VTAK opened at $0.15 on Tuesday. The firm has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $7.79. Catheter Precision has a 52 week low of $0.13 and a 52 week high of $3.20. The company has a quick ratio of 0.18, a current ratio of 0.19 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $2.17 million, a P/E ratio of -0.02 and a beta of -0.99.
About Catheter Precision
Catheter Precision, Inc is a medical device company focused on developing technologies for cardiac electrophysiology, a field involving the diagnosis and treatment of heart-rhythm disorders. Its products are designed to support physicians during procedures used to evaluate and treat cardiac arrhythmias, including ventricular tachycardia and other irregular heart rhythms.
The company’s product portfolio includes the VIVO system, a noninvasive 3D cardiac mapping and navigation platform intended to help clinicians identify the origin of ventricular arrhythmias and plan catheter-ablation procedures.
Read More
- Five stocks we like better than Catheter Precision
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.
